{"id":"piperacillin-tazobactam-or-temocillin","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Diarrhea"},{"rate":"3-10","effect":"Nausea"},{"rate":"2-8","effect":"Rash"},{"rate":"2-5","effect":"Phlebitis at injection site"},{"rate":"1-5","effect":"Headache"},{"rate":"1-3","effect":"Clostridium difficile-associated diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1276310","moleculeType":"Small molecule","molecularWeight":"414.46"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Piperacillin is an extended-spectrum penicillin that disrupts peptidoglycan cross-linking in bacterial cell walls, while tazobactam is a beta-lactamase inhibitor that protects piperacillin from enzymatic degradation by resistant organisms. Temocillin is a beta-methoxy-substituted penicillin with intrinsic resistance to many beta-lactamases. These agents are used to treat serious gram-negative and gram-positive bacterial infections.","oneSentence":"Piperacillin/tazobactam and temocillin are beta-lactam antibiotics that inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins, with tazobactam providing beta-lactamase inhibition to overcome resistance.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:10.967Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Serious gram-negative and gram-positive bacterial infections (piperacillin/tazobactam)"},{"name":"Aerobic gram-negative infections including Enterobacteriaceae (temocillin)"},{"name":"Hospital-acquired and nosocomial infections"}]},"trialDetails":[{"nctId":"NCT04436991","phase":"","title":"Antibiotic Dosing in Geriatric Patients At the Emergency Department","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2018-01-03","conditions":"Elderly Infection, Frailty, Frail Elderly Syndrome","enrollment":180},{"nctId":"NCT05565222","phase":"PHASE3","title":"Piperacillin-tazobactam and Temocillin as Carbapenem-alternatives for the Treatment of Severe Infections Due to Extended-spectrum Beta-lactamase-Producing Gram-negative Enterobacteriaceae in the Intensive Care Unit","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-03-11","conditions":"Sepsis, Septic Shock","enrollment":600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7759,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Piperacillin/tazobactam or temocillin","genericName":"Piperacillin/tazobactam or temocillin","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Piperacillin/tazobactam and temocillin are beta-lactam antibiotics that inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins, with tazobactam providing beta-lactamase inhibition to overcome resistance. Used for Serious gram-negative and gram-positive bacterial infections (piperacillin/tazobactam), Aerobic gram-negative infections including Enterobacteriaceae (temocillin), Hospital-acquired and nosocomial infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}